Economic evaluation of early monotherapy versus delayed monotherapy or combination therapy in patients with acute hepatitis C in Germany

European Journal of Gastroenterology and Hepatology

Volumn 22, Issue 3, 2010, Pages 278-288

  Dintsios, Charalabos Markos ^a,e   Haverkamp, Alexander ^a   Wiegand, Johannes ^c   Gerlach, Tilman ^d   Wedemeyer, Heiner ^b   Pape, Gerd ^d   Manns, Michael Peter ^b   Krauth, Christian ^a  

^a Social Medicine and Health System Research   (Germany)

^b Hanover Medical School   (Canada)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e INSTITUTE FOR QUALITY AND EFFICIENCY IN HEALTH CARE IQWIG   (Germany)

Author keywords

Cost effectiveness; Hepatitis C; Interferon; Ribavirin; Simulationmodel

Indexed keywords

INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; ECONOMIC EVALUATION; FEMALE; GERMANY; HEALTH CARE COST; HEALTH ECONOMICS; HEPATITIS C; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; SIMULATION; THERAPY DELAY; TREATMENT DURATION; TREATMENT RESPONSE;

ACUTE DISEASE; ADULT; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; DRUG THERAPY, COMBINATION; FEMALE; GERMANY; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; LINEAR MODELS; MALE; MIDDLE AGED; MODELS, ECONOMIC; POLYETHYLENE GLYCOLS; PRACTICE GUIDELINES AS TOPIC; RIBAVIRIN; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 76649112731     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32832c7b2e     Document Type: Article

References (59)

1. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341:556-562.
2. Ray KW. Global epidemiology and burden of hepatitis C. Microbes Infect 2002; 4:1219-1225.
3. Robert-Koch-Institut. Yearbook of notifiable infectious diseases, 2002. Berlin: Robert-Koch-Institut; 2003.
4. Robert-Koch-Institut (GBE-Booklets). Emerging and re-emerging infectious diseases. Berlin: Robert-Koch-Institut; 2003.
5. The Global Burden of Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004; 44:20-29.
6. Robert-Koch-Institut (GBE-Booklets). Hepatitis C. Berlin: Robert-Koch-Institut; 2003.
7. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002; 36:S21-S29.
8. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5:558-567.
9. De Rosa FG, Bargiacchi O, Audagnotto S, Garazzino S, Cariti G, Raiteri R, Di Perri G. Dose-dependent and genotype-independent sustained virological response of a 12 week pegylated interferon alpha-2b treatment for acute hepatitis C. J Antimicrob Chemother 2006; 57:360-363.
10. Fozouni B, Guntert B. Determining priorities in German public health-triad between rationing, rationalization and rational allocation. Gesundheitswesen 2000; 62:559-567.
11. Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung MC, Ulsenheimer A, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003; 125:80-88.
12. Manns MP, Meyer S,Wedemeyer H. The German network of excellence for viral hepatitis (Hep-Net). Hepatology 2003; 38:543-544.
13. Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001; 345:1452-1457.
14. Wiegand J, Buggisch P, Boecher W, Zeuzem S, Gelbmann CM, Berg T, et al. Early monotherapy with pegylated interferon alfa-2b for acute hepatitis C infection: the HEP-NET Acute-HCV-II Study. Hepatology 2006; 43:250-256.
15. Drummond M. Methods for the economic evaluation of health care programmes. 2nd ed. reprint ed. Oxford: Oxford University Press; 2000.
16. Zeuzem S. Standard treatment of acute and chronic hepatitis C. Z Gastroenterol 2004; 42:714-719. (Pubitemid 39166161)
17. Dusheiko G, Schmilovitz-Weiss H, Brown D, McOmish F, Yap PL, Sherlock S, et al. Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. Hepatology 1994; 19:13-18.
18. Schreier E, Roggendorf M, Driesel G, Hohne M, Viazov S. Genotypes of hepatitis C virus isolates from different parts of the world. Arch Virol Suppl 1996; 11:185-193.
19. Lehmann M, Meyer MF, Monazahian M, Tillmann HL, Manns MP, Wedemeyer H. High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection. J Med Virol 2004; 73:387-391.
20. Krauth C, Hessel F, Hansmeier T,Wasem J, Seitz R, Schweikert B. Empirical standard costs for health economic evaluation in Germany - a proposal by the working group methods in health economic evaluation. Gesundheitswesen 2005; 67:736-746.
21. Reddy KR. Controlled-release, pegylated, liposomal formulations: new mechanisms in the delivery of injectable drugs. Ann Pharmacother 2000; 34:915-923.
22. Berg T, Hopf U, Stark K, Baumgarten R, Lobeck H, Schreier E. Distribution of hepatitis C virus genotypes in German patients with chronic hepatitis C: correlation with clinical and virological parameters. J Hepatol 1997; 26:484-491.
23. Ross RS, Viazov S, Renzing-Köhler K, Roggendorf M. Changes in the epidemiology of hepatitis C infection in Germany: shift in the predominance of hepatitis C subtypes. J Med Virol 2000; 60:122-125.
24. Meyer MF, Wedemeyer H, Monazahian M, Dreesman J, Manns MP, Lehmann M. Prevalence of hepatitis C in a German prison for young men in relation to country of birth. Epidemiol Infect 2007; 135:274-280.
25. Delwaide J, Bourgeois N, Gerard C, De Maeght S, Mokaddem F, Wain E, et al. Treatment of acute hepatitis C with interferon alpha-2b: early initiation of treatment is the most effective predictive factor of sustained viral response. Aliment Pharmacol Ther 2004; 20:15-22.
26. Wawrzynowicz-Syczewska M, Kubicka J, Lewandowski Z, Boron-Kaczmarska A, Radkowski M. Natural history of acute symptomatic hepatitis type C. Infection 2004; 32:138-143.
27. Nomura H, Sou S, Tanimoto H, Nagahama T, Kimura Y, Hayashi J, et al. Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial. Hepatology 2004; 39:1213-1219.
28. Santantonio T, Sinisi E, Guastadisegni A, Casalino C, Mazzola M, Gentile A, et al. Natural course of acute hepatitis C: a long-term prospective study. Dig Liver Dis 2003; 35:104-113.
29. Kamal SM, Ismail A, Graham CS, He Q, Rasenack JW, Peters T, et al. Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics. Hepatology 2004; 39:1721-1731.
30. Kryczka W, Zarebska-Michaluk D. Treatment of acute hepatitis C. Med Sci Monit 2003; 9 (Suppl 3):22-24.
31. Wedemeyer H, Jackel E, Wiegand J, Cornberg M, Manns MP. Whom? When? How? Another piece of evidence for early treatment of acute hepatitis C. Hepatology 2004; 39:1201-1203.
32. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000; 132:296-305.
33. Vogel W, Graziadei I, Umlauft F, Datz C, Hackl F, Allinger S, et al. High-dose interferon-alpha2b treatment prevents chronicity in acute hepatitis C: a pilot study. Dig Dis Sci 1996; 41 (12 Suppl):81S-85S.
34. Santantonio T, Fasaona M, Sinisi E, Guastadisegni A, Casalino C, Mazzola M, et al. Efficacy of a 24-week course of PEG-interferon a-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clerarnace. J Hepatol 2005; 42:329-333.
35. Kamal SM, Fouly AE, Kamel RR, Hockeenjos B, Al Tawil A, Khalifa KE, et al. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology 2006; 130:632-638.
36. Kamal SM, Moustafa KN, Chen J, Fehr J, Moneim AA, Khalifa KE, et al. Duration of peginterferon therapy in acute hepatitis C: a randomized trial. Hepatology 2006; 43:923-931.
37. Dominguez S, Ghosna J, Valantin MA, Schruniger A, Simon A, Bonnard P, et al. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients. AIDS 2006; 20:1157-1161.
38. Matthews G, Hellard M, Sasadeusz J, Marks P, Yeung B, Baker D, et al. Pegylated interferon alfa-2a (PEG-IFN) +ribavirin (RBV) in HIV infected individuals within the Australian Trial of Acute Hepatitis C (ATAHC) achieves end of treatment response (ETR) in over 80% of individuals. 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2007). Sydney, Australia, July 22-25, 2007. Abstract MOPEB045.
39. Luetkemeyer A, Hare CB, Stansell J, Tien PC, Charlesbois E, Lum P, et al. Clinical presentation and course of acute hepatitis C infection in HIV-infected patients. J Acquir Immune Defic Syndr 2006; 41:31-36.
40. Manns M, McHutchinson JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965. (Pubitemid 32913521)
41. Siebert U, Sroczynski G, Rossol S,Wasem J, Ravens-Sieberer U, Kurth BM, et al. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003; 52:425-432.
42. Siebert U, Sroczynski G, on behalf of the German Hepatitis C Model (GEHMO) Group and the HTA Expert Panel on Hepatitis C. Antiviral therapy for patients with chronic hepatitis C in Germany. Evaluation of effectiveness and cost-effectiveness of initial combination therapy with Interferon/ Peginterferon plus Ribavirin. Series of the German Institute for Medical Documentation and Information commissioned by the Federal Ministry of Health and Social Security. DIMDI 2003; Cologne.
43. Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40:993-999.
44. Siebert U, Sroczynski G, Wasem J, Greiner W, Ravens-Sieberer U, Aidelsburger P, et al. Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon a-2b plus ribavirin as initial treatement of chronic hepatitis C in Germany. Eur J Health Econ 2005; 6:112-123.
45. Siebert U, Sroczynski G, for the German Hepatitis CMGG, HTA Expert Panel on Hepatitis. Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health and Social Security. Int J Technol Assess Health Care 2005; 21:55-65.
46. Poynard T, Regimbeau C, Myers RP, Leroy V, Mathurin P, Opolon P, et al. Interferon for acute hepatitis C. Cochrane Database Syst Rev 2001; 4:CD000369.
47. Jaeckel E, Manns MP. The course and therapy of acute hepatitis C viral infection. Is a prevention of its becoming chronic possible? Z Gastroenterol 2000; 38:387-395.
48. Licata A, Di BD, Schepis F, Shahied L, Craxi A, Camma C.When and how to treat acute hepatitis C? J Hepatol 2003; 39:1056-1062.
49. Rocca P, Bailly F, Chevallier M, Chevallier P, Zoulim F, Trepo C. Early treatment of acute hepatitis C with interferon alpha-2b or interferon alpha-2b plus ribavirin: study of sixteen patients. Gastroenterol Clin Biol 2003; 27:294-299. (Pubitemid 36460426)
50. Lucidarme D, Filoche B. Acute hepatitis C: early, delayed or immediate treatment? Gastroenterol Clin Biol 2004; 28:126-128.
51. De Rosa FG, Bargiacchi O, Audagnotto S, Garazzino S, Cariti G, Veronese L, et al. The early HCV RNA dynamics in patients with acute hepatitis C treated with pegylated interferon-a2b. Antivir Ther 2006; 11:165-171.
52. Wiegand J, Jackel E, Cornberg M, Hinrichsen H, Dietrich M, Kroeger J, et al. Long-term follow-up after successful interferon therapy of acute hepatitis C. Hepatology 2004; 40:98-107.
53. Jaeckel E, Wedemeyer H, Wiegand J, Manns MP. Acute hepatitis C virus infection: to treat or not to treat? Gastroenterology 2004; 126:1219-1220.
54. McHutchison JG,Ware JE, Bayliss MS, Pianko S, Albrecht JK, Cort S, et al. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol 2001; 34:140-147.
55. Chong C, Gulamhussein A, Jenny Heathcote E, Lilly L, Sherman M, Naglie G, et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 2003; 98:630-638.
56. Siebert U, Ravens-Sieberer U, Greiner W, Sroczynski G,Wong JB, Kuntz KM, et al., German Hepatitis C Model (GEHMO) Group. Performance of different utility assessment methods in chronic hepatitis C patients. In: Kind P, Macran S, editors. Proceedings of the 19th Plenary Meeting of the Euro-Qol Group. 13th-14th September 2002 Discussion Papers. York, UK; Centre for Health Economics, University of York: 2003. pp. 175-184.
57. Hofer H,Watkins-Riedel T, Janata O, Penner E, Holzmann H, Steindl-Munda P, et al. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology 2003; 37:60-64. (Pubitemid 36042145)
58. Wiese M, Grüngreiff K, GüthoffW, Lafrenz M, Oesen U, Porst H, for the East German Hepatitis C Study Group. Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany-a 25-year multicenter study. J Hepatol 2005; 43:590-598.
59. Salomon JA,Weinstein MC, Goldie SJ. Taking account of future technology in cost effectiveness analysis. BMJ 2004; 329:733-736.